Xianjun Yu

List of Publications by Citations

308 papers	7,129 citations	44 h-index	69 g-index
324 ext. papers	10,236 ext. citations	6.8 avg, IF	6.12 L-index

#	Paper	IF	Citations
308	Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. *Journal of Hematology and Oncology*, **2020**, 13, 110	22.4	208
307	The role of necroptosis in cancer biology and therapy. *Molecular Cancer*, **2019**, 18, 100	42.1	206
306	The role of collagen in cancer: from bench to bedside. *Journal of Translational Medicine*, **2019**, 17, 309	8.5	196
305	Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. *Nature Genetics*, **2016**, 48, 747-57	36.3	187
304	Overcoming drug resistance in pancreatic cancer. *Expert Opinion on Therapeutic Targets*, **2011**, 15, 817-28	6.4	157
303	Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. *Nature Genetics*, **2011**, 44, 62-6	36.3	141
302	Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. *Clinical Cancer Research*, **2010**, 16, 2740-50	12.9	141
301	Carbon nanotubes in cancer diagnosis and therapy. *Biochimica Et Biophysica Acta: Reviews on Cancer* , **2010**, 1806, 29-35	11.2	130
300	LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. *International Journal of Pharmaceutics*, **2010**, 385, 150-6	6.5	121
299	Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. *Annals of Surgical Oncology*, **2015**, 22, 670-6	3.1	108
298	Angiogenesis in pancreatic cancer: current research status and clinical implications. *Angiogenesis*, **2019**, 22, 15-36	10.6	94
297	Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. *Cancer Letters*, **2014**, 346, 273-7	9.9	92
296	Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. *Journal of Clinical Oncology*, **2017**, 35, 274-280	2.2	91
295	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. *Theranostics*, **2018**, 8, 5072-5087	12.1	91
294	Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. *Annals of Surgical Oncology*, **2017**, 24, 561-568	3.1	90
293	Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. *International Journal of Cancer*, **2017**, 140, 2344-2350	7.5	88
292	The microbiota and microbiome in pancreatic cancer: more influential than expected. *Molecular Cancer*, **2019**, 18, 97	42.1	88

291	ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. *Cell Research*, **2015**, 25, 561-73	24.7	88
290	Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. *Annals of Surgery*, **2017**, 265, 800-805	7.8	75
289	Toll-Like Receptor 4/MyD88-Mediated Signaling of Hepcidin Expression Causing Brain Iron Accumulation, Oxidative Injury, and Cognitive Impairment After Intracerebral Hemorrhage. *Circulation*, **2016**, 134, 1025-1038	16.7	75
288	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. *Experimental and Molecular Medicine*, **2017**, 49, e406	12.8	75
287	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. *Cancer Letters*, **2016**, 374, 127-135	9.9	73
286	A preoperative serum signature of CEA+/CA125+/CA19-9 ≥1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. *International Journal of Cancer*, **2015**, 136, 2216-27	7.5	71
285	Combinational therapy: new hope for pancreatic cancer?. *Cancer Letters*, **2012**, 317, 127-35	9.9	70
284	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. *Molecular Cancer*, **2020**, 19, 49	42.1	69
283	A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. *EMBO Molecular Medicine*, **2013**, 5, 1322-34	12	69
282	Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1093-102	8.8	65
281	RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. *Cancer Biology and Therapy*, **2012**, 13, 206-15	4.6	65
280	Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling. *Oncogene*, **2018**, 37, 5843-5857	9.2	62
279	FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. *Clinical Cancer Research*, **2016**, 22, 3950-60	12.9	60
278	Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. *Molecular Cancer*, **2021**, 20, 131	42.1	59
277	Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. *OncoTargets and Therapy*, **2017**, 10, 4591-4598	4.4	56
276	Intratumoral ESMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer. *PLoS ONE*, **2013**, 8, e71189	3.7	55
275	CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. *Journal of Gastrointestinal Surgery*, **2013**, 17, 2092-8	3.3	51
274	Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. *Acta Pharmacologica Sinica*, **2009**, 30, 1337-43	8	50

273	MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. *Oncotarget*, **2015**, 6, 14440-55	3.3	49
272	A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. *Theranostics*, **2020**, 10, 3967-3979	12.1	49
271	LSD1 sustains pancreatic cancer growth via maintaining HIF1□dependent glycolytic process. *Cancer Letters*, **2014**, 347, 225-32	9.9	48
270	Pilot study of targeting magnetic carbon nanotubes to lymph nodes. *Nanomedicine*, **2009**, 4, 317-30	5.6	48
269	High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. *Oncologist*, **2010**, 15, 732-43	5.7	46
268	Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. *Oncotarget*, **2016**, 7, 5943-56	3.3	46
267	The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients. *Pancreatology*, **2016**, 16, 1080-1084	3.8	46
266	Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, **2019**, 26, 635-643	3.1	45
265	PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. *Cell Communication and Signaling*, **2019**, 17, 30	7.5	44
264	Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. *Gut*, **2020**, 69, 888-900	19.2	44
263	UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. *Cancer Letters*, **2019**, 452, 226-236	9.9	42
262	Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. *Journal of Hematology and Oncology*, **2020**, 13, 130	22.4	42
261	Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. *Annals of Surgery*, **2019**, 269, 944-950	7.8	41
260	Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation. *Nuclear Medicine Communications*, **2013**, 34, 533-9	1.6	40
259	Clinical experiences of solid pseudopapillary tumors of the pancreas in China. *Journal of Gastroenterology and Hepatology (Australia)*, **2008**, 23, 1847-51	4	40
258	Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncology, The*, **2020**, 21, 1489-1499	21.7	39
257	Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncology, The*, **2020**, 21, 1500-1512	21.7	38
256	The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis. *Hepatobiliary and Pancreatic Diseases International*, **2018**, 17, 95-100	2.1	37

255	Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization. *Journal of Hematology and Oncology*, **2012**, 5, 69	22.4	37
254	Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. *Oncology Letters*, **2017**, 13, 1165-1174	2.6	36
253	Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1 axis. *Molecular Cancer*, **2014**, 13, 187	42.1	36
252	Targeted drug delivery in pancreatic cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2010**, 1805, 97-104	11.2	36
251	Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. *Nano Letters*, **2019**, 19, 3527-3534	11.5	35
250	FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. *Redox Biology*, **2021**, 38, 101807	11.3	35
249	Upregulation of the Long Noncoding RNA SNHG3 Promotes Lung Adenocarcinoma Proliferation. *Disease Markers*, **2018**, 2018, 5736716	3.2	33
248	Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. *Surgery*, **2017**, 161, 373-384	3.6	33
247	Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. *Molecular Cancer Research*, **2017**, 15, 201-212	6.6	32
246	Kras mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer. *Cancer Letters*, **2019**, 446, 103-111	9.9	32
245	MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer. *Cancer Letters*, **2018**, 418, 167-175	9.9	32
244	Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. *Cancer Letters*, **2018**, 412, 188-193	9.9	32
243	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. *Neuroendocrinology*, **2018**, 107, 237-245	5.6	32
242	Quantum dots in cancer therapy. *Expert Opinion on Drug Delivery*, **2012**, 9, 47-58	8	32
241	TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. *Autophagy*, **2020**, 16, 486-500	10.2	32
240	Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. *Cancer Letters*, **2015**, 360, 227-33	9.9	31
239	A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression. *Molecular Cancer Research*, **2013**, 11, 1508-20	6.6	31
238	The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer. *Annals of Translational Medicine*, **2020**, 8, 1347	3.2	30

237	Ferroptosis: Final destination for cancer?. *Cell Proliferation*, **2020**, 53, e12761	7.9	30
236	Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. *International Journal of Oncology*, **2017**, 51, 686-694	4.4	29
235	Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. *International Journal of Oncology*, **2013**, 42, 979-84	4.4	29
234	The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. *Molecular Cancer*, **2019**, 18, 184	42.1	29
233	Role of angiogenesis in pancreatic cancer biology and therapy. *Biomedicine and Pharmacotherapy*, **2018**, 108, 1135-1140	7.5	29
232	Pancreatic cancer: BRCA mutation and personalized treatment. *Expert Review of Anticancer Therapy* , **2015**, 15, 1223-31	3.5	28
231	Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. *Pancreatology*, **2014**, 14, 295-301	3.8	28
230	The Significance of Liquid Biopsy in Pancreatic Cancer. *Journal of Cancer*, **2018**, 9, 3417-3426	4.5	28
229	ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. *Cancer Letters*, **2017**, 388, 303-311	9.9	27
228	New insights into perineural invasion of pancreatic cancer: More than pain. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2016**, 1865, 111-22	11.2	27
227	PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. *Cancer Research*, **2019**, 79, 133-145	10.1	27
226	microRNA signature for human pancreatic cancer invasion and metastasis. *Experimental and Therapeutic Medicine*, **2012**, 4, 181-187	2.1	26
225	The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. *PeerJ*, **2020**, 8, e9602	3.1	26
224	Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1875, 188409	11.2	26
223	Human profilin 1 is a negative regulator of CTL mediated cell-killing and migration. *European Journal of Immunology*, **2017**, 47, 1562-1572	6.1	25
222	Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. *Pancreas*, **2019**, 48, 817-822	2.6	25
221	Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2015**, 1855, 43-9	11.2	24
220	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. *Cellular and Molecular Life Sciences*, **2018**, 75, 1001-1012	10.3	24

219	Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition. *Hepatobiliary and Pancreatic Diseases International*, **2014**, 13, 386-94	2.1	24
218	Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). *International Journal of Oncology*, **2017**, 50, 567-574	4.4	23
217	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. *Cell Death and Disease*, **2018**, 9, 321	9.8	23
216	Critical role of oncogenic KRAS in pancreatic cancer (Review). *Molecular Medicine Reports*, **2016**, 13, 4943-49	2.9	23
215	Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. *American Journal of Cancer Research*, **2018**, 8, 332-353	4.4	23
214	Hypoxia: a barricade to conquer the pancreatic cancer. *Cellular and Molecular Life Sciences*, **2020**, 77, 3077-3083	10.3	23
213	Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥1,000 U/mL. *Scientific Reports*, **2016**, 6, 19222	4.9	22
212	Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. *Journal of Hematology and Oncology*, **2018**, 11, 14	22.4	22
211	Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. *International Journal of Oncology*, **2013**, 42, 2046-52	4.4	22
210	Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. *Pancreatology*, **2011**, 11, 595-600	3.8	22
209	Management of a malignant case of solid pseudopapillary tumor of pancreas: a case report and literature review. *Pancreas*, **2012**, 41, 1336-40	2.6	22
208	Aberrant hepatic artery in patients undergoing pancreaticoduodenectomy. *Pancreatology*, **2008**, 8, 50-4	3.8	22
207	Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2020**, 1874, 188392	11.2	22
206	Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors. *Oncology Letters*, **2017**, 13, 2454-2458	2.6	21
205	Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patients. *Pancreatology*, **2019**, 19, 681-685	3.8	21
204	Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. *World Journal of Gastroenterology*, **2020**, 26, 828-838	5.6	21
203	Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. *Cancer Medicine*, **2019**, 8, 5903-5915	4.8	20
202	Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. *Medicine (United States)*, **2015**, 94, e751	1.8	20

201	A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice. *Investigational New Drugs*, **2011**, 29, 861-72	4.3	20
200	Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. *Pancreatology*, **2016**, 16, 1057-1062	3.8	20
199	GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. *Cell Death and Disease*, **2018**, 9, 1187	9.8	20
198	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. *Oncology Reports*, **2017**, 38, 2069-2077	3.5	19
197	New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. *Pancreatology*, **2018**, 18, 971-976	3.8	19
196	Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin β1-actin complex in breast cancer cells. *Journal of Cellular and Molecular Medicine*, **2012**, 16, 824-35	5.6	19
195	Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. *Drug Design, Development and Therapy*, **2015**, 9, 1247-55	4.4	19
194	A school-based study of irritable bowel syndrome in medical students in beijing, china: prevalence and some related factors. *Gastroenterology Research and Practice*, **2014**, 2014, 124261	2	19
193	Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. *BioMed Research International*, **2014**, 2014, 925845	3	19
192	MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. *International Journal of Cancer*, **2018**, 143, 2919-2931	7.5	19
191	Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. *Carcinogenesis*, **2013**, 34, 1001-5	4.6	18
190	Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. *Hepatobiliary and Pancreatic Diseases International*, **2014**, 13, 634-41	2.1	18
189	Development of a unique mouse model for pancreatic cancer lymphatic metastasis. *International Journal of Oncology*, **2012**, 41, 1662-8	4.4	18
188	Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. *Theranostics*, **2021**, 11, 2755-2769	12.1	18
187	RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. *International Journal of Oncology*, **2018**, 52, 1105-1116	4.4	17
186	Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases. *Journal of Surgical Research*, **2012**, 172, e11-7	2.5	17
185	Applications of single-cell sequencing in cancer research: progress and perspectives. *Journal of Hematology and Oncology*, **2021**, 14, 91	22.4	17
184	Energy sources identify metabolic phenotypes in pancreatic cancer. *Acta Biochimica Et Biophysica Sinica*, **2016**, 48, 969-979	2.8	17

183	Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. *Pancreatology*, **2015**, 15, 253-8	3.8	16
182	Stroma and pancreatic ductal adenocarcinoma: an interaction loop. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2012**, 1826, 170-8	11.2	16
181	The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. *Oncotarget*, **2014**, 5, 3895-906	3.3	16
180	The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2019**, 1872, 188311	11.2	15
179	A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-TNM staging. *Surgery*, **2018**, 163, 1280-1294	3.6	15
178	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2016**, 1866, 177-188	11.2	15
177	Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET). *International Journal of Oncology*, **2016**, 49, 1991-2000	4.4	15
176	Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	15
175	Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. *American Journal of Cancer Research*, **2020**, 10, 1182-1193	4.4	15
174	Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR/ERK pathway. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 5443-5456	5.6	15
173	Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. *Oncology Letters*, **2017**, 14, 6795-6800	2.6	14
172	A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma **2019**, 7, 233		14
171	Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. *Cell Proliferation*, **2019**, 52, e12603	7.9	14
170	Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. *Cancer Medicine*, **2020**, 9, 2153-2159	4.8	14
169	dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. *Cell Proliferation*, **2018**, 51, e12456	7.9	14
168	Proteomic analysis of differential proteins in pancreatic carcinomas: Effects of MBD1 knock-down by stable RNA interference. *BMC Cancer*, **2008**, 8, 121	4.8	14
167	The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	14
166	A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. *International Journal of Oncology*, **2017**, 50, 1792-1800	4.4	13

165	Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. *Surgery*, **2015**, 158, 1211-8	3.6	13
164	Prognostic Value of the C-Reactive Protein/Lymphocyte Ratio in Pancreatic Cancer. *Annals of Surgical Oncology*, **2020**, 27, 4017-4025	3.1	13
163	Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. *Pancreatology*, **2018**, 18, 671-677	3.8	13
162	SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer. *Journal of Cancer*, **2019** , 10, 2670-2678	4.5	13
161	Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor. *World Journal of Gastroenterology*, **2019**, 25, 6248-6257	5.6	13
160	The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. *Journal of Pancreatology*, **2019**, 2, 16-21	1.9	13
159	The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. *Annals of Surgery*, **2020**, 271, 559-565	7.8	13
158	Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, **2018**, 25, 3984-3993	3.1	13
157	Laparoscopic pancreaticoduodenectomy: are the best times coming?. *World Journal of Surgical Oncology*, **2019**, 17, 81	3.4	12
156	Reflections on depletion of tumor stroma in pancreatic cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2019**, 1871, 267-272	11.2	12
155	Strategies for pancreatic anastomosis after pancreaticoduodenectomy: What really matters?. *Hepatobiliary and Pancreatic Diseases International*, **2018**, 17, 22-26	2.1	12
154	The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC). *International Journal of Oncology*, **2016**, 48, 900-7	4.4	12
153	Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. *Pancreas*, **2018**, 47, 742-747	2.6	12
152	(18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. *International Journal of Oncology*, **2014**, 45, 1531-6	4.4	12
151	CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. *Cancer Letters*, **2017**, 385, 46-50	9.9	12
150	International expert consensus on laparoscopic pancreaticoduodenectomy. *Hepatobiliary Surgery and Nutrition*, **2020**, 9, 464-483	2.1	12
149	Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. *Molecular Cancer*, **2021**, 20, 106	42.1	12
148	The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. *Cancer Management and Research*, **2019**, 11, 3327-3337	3.6	11

147	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. *Cancer Cell International*, **2019**, 19, 49	6.4	11
146	Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-B-IL-18 feedback loop. *Cell Proliferation*, **2020**, 53, e12816	7.9	11
145	Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. *Journal of Cancer*, **2019**, 10, 4420-4429	4.5	11
144	Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. *Cancer Letters*, **2015**, 359, 165-8	9.9	11
143	Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. *Frontiers in Immunology*, **2021**, 12, 648917	8.4	11
142	Prognostic value of -glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. *Cancer Medicine*, **2019**, 8, 572-584	4.8	11
141	Surgical Resection for Metastatic Tumors in the Pancreas: A Single-Center Experience and Systematic Review. *Annals of Surgical Oncology*, **2019**, 26, 1649-1656	3.1	10
140	Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. *Cancer Chemotherapy and Pharmacology*, **2017**, 80, 507-516	3.5	10
139	FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. *American Journal of Cancer Research*, **2019**, 9, 2650-2664	4.4	10
138	Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis suppression of sirtuin 3 in pancreatic cancer. *World Journal of Gastroenterology*, **2018**, 24, 4893-4905	5.6	10
137	Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. *Cancer Cell International*, **2019**, 19, 309	6.4	10
136	Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. *Cancer Immunology, Immunotherapy*, **2018**, 67, 1815-1823	7.4	10
135	Analysis of gene expression profiles in pancreatic carcinoma by using cDNA microarray. *Hepatobiliary and Pancreatic Diseases International*, **2003**, 2, 467-70	2.1	10
134	Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. *Oncology Letters*, **2017**, 13, 3163-3168	2.6	9
133	Revised nodal stage for pancreatic neuroendocrine tumors. *Pancreatology*, **2017**, 17, 599-604	3.8	9
132	Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. *European Journal of Surgical Oncology*, **2019**, 45, 1069-1076	3.6	9
131	The Loss of Expression Associated with a Strongly Activated Hedgehog Signaling Pathway Predicts Poor Prognosis in Resected Pancreatic Cancer. *Journal of Cancer*, **2019**, 10, 4123-4131	4.5	9
130	Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients. *Journal of Zhejiang University: Science B*, **2014**, 15, 907-14	4.5	9

129	Precise and efficient silencing of mutant Kras by CRISPR-CasRx controls pancreatic cancer progression. *Theranostics*, **2020**, 10, 11507-11519	12.1	9
128	Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. *Journal of Cancer*, **2017**, 8, 3615-3622	4.5	8
127	Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. *BMC Cancer*, **2017**, 17, 521	4.8	8
126	High throughput gene sequencing reveals altered landscape in DNA damage responses and chromatin remodeling in sporadic pancreatic neuroendocrine tumors. *Pancreatology*, **2018**, 18, 318-327	3.8	8
125	Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study. *Cancer Medicine*, **2018**, 7, 4361-4370	4.8	8
124	Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. *Cancer Medicine*, **2019**, 8, 5223-5231	4.8	8
123	The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. *Cancer Management and Research*, **2019**, 11, 8781-8788	3.6	8
122	Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?. *Oncotarget*, **2016**, 7, 29177-86	3.3	8
121	The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives. *Journal of Hematology and Oncology*, **2020**, 13, 154	22.4	8
120	TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway. *Oncogene*, **2020**, 39, 5825-5838	9.2	8
119	Selecting chemotherapy for pancreatic cancer: Far away or so close?. *Seminars in Oncology*, **2019**, 46, 39-47	5.5	8
118	Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts. *Cell Death and Disease*, **2021**, 12, 662	9.8	8
117	Application of "papillary-like main pancreatic duct invaginated" pancreaticojejunostomy for normal soft pancreas cases. *Scientific Reports*, **2013**, 3, 2068	4.9	7
116	Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC). *International Journal of Oncology*, **2015**, 47, 1512-6	4.4	7
115	Significance of caveolin-1 regulators in pancreatic cancer. *Asian Pacific Journal of Cancer Prevention*, **2013**, 14, 4501-7	1.7	7
114	Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. *Cancers*, **2021**, 13,	6.6	7
113	Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). *BMJ Open*, **2019**, 9, e033452	3	7
112	Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. *European Journal of Surgical Oncology*, **2019**, 45, 769-775	3.6	7

111	Tumor-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumor. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	7
110	The superiority of [Ga]-FAPI-04 over [F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1248-1249	8.8	7
109	Killing the "BAD": Challenges for immunotherapy in pancreatic cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2020**, 1874, 188384	11.2	6
108	Differentiation of solid-pseudopapillary tumors of the pancreas from pancreatic neuroendocrine tumors by using endoscopic ultrasound. *Clinics and Research in Hepatology and Gastroenterology*, **2020**, 44, 947-953	2.4	6
107	Clinicopathological features and prognostic validity of the European Neuroendocrine Tumor Society (ENETS) and American Joint Committee on Cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. *Cancer Medicine*, **2019**, 8, 5000-5011	4.8	6
106	A new approach to produce amino-carbon nanotubes as plasmid transfection vector by [2 + 1] cycloaddition of nitrenes. *Journal of Nanoparticle Research*, **2011**, 13, 33-38	2.3	6
105	The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. *Aging*, **2020**, 12, 24228-24241	5.6	6
104	A robust gene expression-based prognostic risk score predicts overall survival of lung adenocarcinoma patients. *Oncotarget*, **2018**, 9, 6862-6871	3.3	6
103	Lewis antigen-negative pancreatic cancer: An aggressive subgroup. *International Journal of Oncology*, **2020**, 56, 900-908	4.4	6
102	Cancer-associated fibroblasts in therapeutic resistance of pancreatic cancer: Present situation, predicaments, and perspectives. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2020**, 1874, 188444	11.2	6
101	Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. *Experimental Hematology and Oncology*, **2020**, 9, 28	7.8	6
100	Emerging roles of the solute carrier family in pancreatic cancer. *Clinical and Translational Medicine*, **2021**, 11, e356	5.7	6
99	Retraction: Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 □1,000 U/mL. *Scientific Reports* , **2016**, 6, 25115	4.9	6
98	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. *Cancer Letters*, **2021**, 499, 265-278	9.9	6
97	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. *Acta Pharmacologica Sinica*, **2021**, 42, 1725-1741	8	6
96	Intrinsic Contact Between T and N Classifications in Resected Well-Moderately Differentiated Locoregional Pancreatic Neuroendocrine Neoplasms. *Annals of Surgical Oncology*, **2018**, 25, 647-654	3.1	6
95	Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. *Pancreatology*, **2019**, 19, 472-477	3.8	5
94	Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. *Computational and Structural Biotechnology Journal*, **2020**, 18, 3606-3614	6.8	5

93	Roux-en-Y pancreaticojejunostomy reconstruction after deep enucleation of benign or borderline pancreatic lesions: a single-institution experience. *Hpb*, **2016**, 18, 145-152	3.8	5
92	Developmental plasticity of stem cells and diseases. *Medical Hypotheses*, **2010**, 75, 507-10	3.8	5
91	Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
90	Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors **2020**, 8,		5
89	Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. *Cancer Cell International*, **2021**, 21, 196	6.4	5
88	Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors. *Frontiers in Immunology*, **2021**, 12, 577517	8.4	5
87	Overcoming chemoresistance by targeting reprogrammed metabolism: the AchillesN heel of pancreatic ductal adenocarcinoma. *Cellular and Molecular Life Sciences*, **2021**, 78, 5505-5526	10.3	5
86	Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. *Cancers*, **2019**, 11,	6.6	5
85	Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFR3-ERK pathway in pancreatic ductal adenocarcinoma. *International Journal of Cancer*, **2021**, 148, 1756-1767	7.5	5
84	A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. *Journal of Gastroenterology*, **2021**, 56, 395-405	6.9	5
83	Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms. *Cancer Management and Research*, **2021**, 13, 107-115	3.6	5
82	Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. *Oncology Letters*, **2017**, 13, 881-886	2.6	4
81	A comprehensive comparison of clinicopathologic and imaging features of incidental/symptomatic non-functioning pancreatic neuroendocrine tumors: A retrospective study of a single center. *Pancreatology*, **2015**, 15, 519-524	3.8	4
80	AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN. *World Journal of Surgical Oncology*, **2019**, 17, 137	3.4	4
79	Clinical and Prognostic Implications of (WAF1/CIP1) Expression in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis. *Disease Markers*, **2020**, 2020, 6520259	3.2	4
78	A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study. *Neuroendocrinology*, **2021**, 111, 752-763	5.6	4
77	Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. *Annals of Translational Medicine*, **2020**, 8, 860	3.2	4
76	Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. *Oncogene*, **2020**, 39, 6572-6588	9.2	4

75	Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. *Frontiers in Endocrinology*, **2021**, 12, 679000	5.7	4
74	Development and Validation of a New Nomogram for Predicting Clinically Relevant Postoperative Pancreatic Fistula After Pancreatoduodenectomy. *World Journal of Surgery*, **2021**, 45, 261-269	3.3	4
73	Clinical application of Tc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms. *Annals of Nuclear Medicine*, **2018**, 32, 446-452	2.5	4
72	Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. *Briefings in Bioinformatics*, **2021**,	13.4	4
71	ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, **2019**, 26, 571-572	3.1	3
70	HNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR. *Acta Biochimica Et Biophysica Sinica*, **2020**, 52, 241-250	2.8	3
69	Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. *Surgery*, **2018**, 163, 1080-1089	3.6	3
68	SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.. *Cancer Letters*, **2022**, 530, 142-142	9.9	3
67	Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis. *Aging*, **2020**, 13, 2031-2048	5.6	3
66	Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer.. *Biomaterials*, **2021**, 280, 121306	15.6	3
65	The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). *Journal of Pancreatology*, **2021**, 4, 1-17	1.9	3
64	Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. *Frontiers in Oncology*, **2021**, 11, 643465	5.3	3
63	Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. *Gland Surgery*, **2021**, 10, 1564-1575	2.2	3
62	Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1875, 188484	11.2	3
61	Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features. *Bioengineered*, **2021**, 12, 3593-3602	5.7	3
60	Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. *OncoTargets and Therapy*, **2018**, 11, 4591-4608	4.4	3
59	Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis.. *Cell Proliferation*, **2021**, e13167	7.9	3
58	Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms. *Annals of Surgery*, **2020**, 275,	7.8	2

57	Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients. *Cancer Management and Research*, **2020**, 12, 6727-6737	3.6	2
56	Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer. *Experimental Hematology and Oncology*, **2020**, 9,	7.8	2
55	From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors. *Frontiers in Immunology*, **2021**, 12, 654660	8.4	2
54	Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). *Hepatobiliary and Pancreatic Diseases International*, **2021**, 20, 163-172	2.1	2
53	Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021). *Journal of Pancreatology*, **2021**, 4, 49-66	1.9	2
52	Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis. *Frontiers in Endocrinology*, **2021**, 12, 691557	5.7	2
51	ASO Author Reflections: C-Reactive Protein/Lymphocyte Ratio as a Promising Marker for Predicting Survival in Pancreatic Cancer. *Annals of Surgical Oncology*, **2020**, 27, 4026-4027	3.1	2
50	High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour. *Endocrine*, **2021**, 71, 494-501	4	2
49	Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. *International Journal of Biological Sciences*, **2021**, 17, 2666-2682	11.2	2
48	MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting Purine Synthesis and Glycolysis in Pancreatic Cancer. *Cancer Research*, **2021**, 81, 4964-4980	10.1	2
47	The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context.. *Frontiers in Oncology*, **2022**, 12, 862743	5.3	2
46	Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: Randomized controlled trials are needed. *Journal of Surgical Oncology*, **2019**, 120, 1284-1285	2.8	1
45	Neoadjuvant Treatment for Pancreatic Cancer: Still a Controversial Issue?. *Journal of Clinical Oncology*, **2020**, 38, 2943-2944	2.2	1
44	Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. *Pancreatology*, **2020**, 20, 716-721	3.8	1
43	Antitumor Effect of Cycle Inhibiting Factor Expression in Colon Cancer VNP20009. *Anti-Cancer Agents in Medicinal Chemistry*, **2020**, 20, 1722-1727	2.2	1
42	Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas. *Experimental and Therapeutic Medicine*, **2020**, 20, 158	2.1	1
41	Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?. *Critical Reviews in Oncology/Hematology*, **2021**, 167, 103493	7	1
40	Function and regulation of F-box/WD repeat-containing protein 7. *Oncology Letters*, **2020**, 20, 1526-1534	2.6	1

39	AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward?. *European Journal of Surgical Oncology*, **2020**, 46, 703	3.6	1
38	Risk factors of postoperative recurrence and potential candidate of adjuvant radiotherapy in lung adenosquamous carcinoma. *Journal of Thoracic Disease*, **2020**, 12, 5593-5602	2.6	1
37	Supraclavicular Recurrence in Completely Resected (y)pN2 Non-Small Cell Lung Cancer: Implications for Postoperative Radiotherapy. *Frontiers in Oncology*, **2020**, 10, 1414	5.3	1
36	A Novel Validated Recurrence Stratification System Based on F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. *Frontiers in Oncology*, **2021**, 11, 650266	5.3	1
35	FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. *Acta Biochimica Et Biophysica Sinica*, **2021**, 53, 997-1008	2.8	1
34	Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms. *World Journal of Gastroenterology*, **2021**, 27, 2895-2909	5.6	1
33	Body Composition and Response and Outcome of Neoadjuvant Treatment for Pancreatic Cancer. *Nutrition and Cancer*, **2021**, 1-10	2.8	1
32	Predictive Values of Preoperative Markers for Resectable Pancreatic Body and Tail Cancer Determined by MDCT to Detect Occult Metastases. *World Journal of Surgery*, **2021**, 45, 2185-2190	3.3	1
31	ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. *Cancer Cell International*, **2021**, 21, 514	6.4	1
30	SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. *Acta Biochimica Et Biophysica Sinica*, **2021**, 53, 1614-1624	2.8	1
29	High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. *World Journal of Surgical Oncology*, **2021**, 19, 35	3.4	1
28	Inhibition of SET domain-containing (lysine methyltransferase) 7 alleviates cognitive impairment through suppressing the activation of NOD-like receptor protein 3 inflammasome in isoflurane-induced aged mice.. *Human and Experimental Toxicology*, **2022**, 41, 9603271211061497	3.4	1
27	Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer.. *EBioMedicine*, **2022**, 79, 104016	8.8	1
26	Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.. *BMC Surgery*, **2022**, 22, 160	2.3	1
25	Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. *Cancer Control*, **2020**, 27, 1073274820915947	2.2	0
24	Pevonedistat Suppresses Pancreatic Cancer Growth Inactivation of the Neddylation Pathway.. *Frontiers in Oncology*, **2022**, 12, 822039	5.3	0
23	Prognosis of distal pancreatic cancers controlled by stage. *Experimental and Therapeutic Medicine*, **2020**, 20, 1091-1097	2.1	0
22	Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma. *Frontiers in Oncology*, **2021**, 11, 674897	5.3	0

21	The clinical characteristics and survival associations of pancreatic neuroendocrine tumors: does age matter?. *Gland Surgery*, **2021**, 10, 574-583	2.2	0
20	Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. *Frontiers in Oncology*, **2021**, 11, 640820	5.3	0
19	ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. *Annals of Surgical Oncology*, **2018**, 25, 3994-3995	3.1	0
18	TGF-β-induced RAP2 regulates invasion in pancreatic cancer.. *Acta Biochimica Et Biophysica Sinica*, **2022**, 54, 361-369	2.8	0
17	The optimal duration of capecitabine plus temozolomide in patients with well-differentiated pancreatic NETs´with or without maintenance therapy.. *Journal of Neuroendocrinology*, **2022**, e13112	3.8	0
16	Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial.. *BMJ Open*, **2022**, 12, e057128	3	0
15	Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).. *European Journal of Cancer*, **2022**, 169, 1-9	7.5	0
14	ASO Author Reflections: Resection for Metastasis to the Pancreas-Worthwhile for Selected Patients. *Annals of Surgical Oncology*, **2019**, 26, 696-697	3.1	
13	Outcomes of Lymph Node Dissection for Nonmetastatic Pancreatic Neuroendocrine Tumors: To Dissect or Not To Dissect. *Annals of Surgical Oncology*, **2019**, 26, 872-873	3.1	
12	The impact of the nodal status and resection margin on the effectiveness of adjuvant chemotherapy for pancreatic cancer: It calls for more careful evaluation. *Journal of Surgical Oncology*, **2019**, 120, 1053-1054	2.8	
11	Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer". *Annals of Surgery*, **2021**, 274, e800-e801	7.8	
10	Active surveillance in metastatic pancreatic neuroendocrine tumors: A 20-year single-institutional experience. *World Journal of Clinical Cases*, **2020**, 8, 3751-3762	1.6	
9	Validation and head-to-head comparison of four models for predicting malignancy of intraductal papillary mucinous neoplasm of the pancreas: A study based on endoscopic ultrasound findings. *World Journal of Gastrointestinal Oncology*, **2019**, 11, 1043-1053	3.4	
8	Understanding genetic features of pancreatic neoplasm. *Chinese Clinical Oncology*, **2019**, 8, 15	2.3	
7	Tumor mutation burden analysis in a 5,660 cancer patient cohort reveals cancer type-specific mechanisms for high mutation burden.. *Journal of Clinical Oncology*, **2019**, 37, 2589-2589	2.2	
6	Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?. *Asian Pacific Journal of Cancer Prevention*, **2015**, 16, 661-6	1.7	
5	Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy. *JAMA Surgery*, **2020**, 155, 267-268	5.4	
4	Pancréatectomie totale laparoscopique avec conservation de la rate pour TIPMP (avec vidéo). *Journal De Chirurgie Viscérale*, **2020**, 157, 453-454	0	

3	ASO Author Reflections: Contact Between T and N Classifications in Pancreatic Neuroendocrine Neoplasms. *Annals of Surgical Oncology*, **2018**, 25, 814-815	3.1
2	Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. *Clinical and Translational Medicine*, **2021**, 11, e398	5.7
1	The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma.. *Journal of Oncology*, **2022**, 2022, 4148805	4.5